Table 2 Characteristics of confirmed mumps cases and outbreaks according to circulating virus genotypes. Catalonia 2007–2011
From: Mumps: MMR vaccination and genetic diversity of mumps virus, 2007–2011 in Catalonia, Spain
CASES | Confirmed cases | Laboratory-confirmed cases | Genotype G | Genotype D | Othersa | |||||
N | % | N | % | N | % | N | % | N | % | |
Gender | 581 | 364 | 126 | 23 | 5 | |||||
Male | 347 | 59.7% | 201 | 55.2% | 78 | 61.9% | 11 | 47.8% | 4 | 80.0% |
Female | 234 | 40.3% | 163 | 44.8% | 48 | 38.1% | 12 | 52.2% | 1 | 20.0% |
Age group (years) | ||||||||||
< 1 | 4 | 0.7% | 2 | 0.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
1–4 | 69 | 11.9% | 34 | 9.3% | 3 | 2.4% | 5 | 21.7% | 0 | 0.0% |
5–14 | 209 | 36.0% | 116 | 31.9% | 32 | 25.4% | 13 | 56.5% | 3 | 60.0% |
15–24 | 173 | 29.8% | 111 | 30.5% | 56 | 44.4% | 1 | 4.3% | 0 | 0.0% |
25–34 | 75 | 12.9% | 78 | 21.4% | 28 | 22.2% | 4 | 17.4% | 1 | 20.0% |
≥ 35 | 51 | 8.8% | 23 | 6.3% | 7 | 5.6% | 0 | 0.0% | 1 | 20.0% |
Year | ||||||||||
2007 | 272 | 46.8% | 204 | 56.0% | 90 | 71.4% | 1 | 4.3% | 1 | 20.0% |
2008 | 85 | 14.6% | 56 | 15.4% | 2 | 1.6% | 10 | 43.5% | 3 | 60.0% |
2009 | 56 | 9.6% | 22 | 6.0% | 8 | 6.3% | 1 | 4.3% | 1 | 20.0% |
2010 | 68 | 11.7% | 30 | 8.2% | 5 | 4.0% | 8 | 34.8% | 0 | 0.0% |
2011 | 100 | 17.2% | 52 | 14.3% | 21 | 16.7% | 3 | 13.0% | 0 | 0.0% |
Laboratory tests | 364 | 62.6% | ||||||||
rtRT-PCR assays | 160 | 44.0% | 108 | 85.7% | 22 | 95.7% | 4 | 80.0% | ||
IgM assays | 166 | 45.6% | – | – | – | |||||
Both tests | 30 | 8.2% | 18 | 14.3% | 1 | 4.3% | 1 | 20.0% | ||
Seroconversion | 8 | 2.2% | – | – | – | |||||
Epidemiologically-linked cases | 217 | 37.4% | 364 | |||||||
Vaccination status | ||||||||||
Non-vacinated | 150 | 25.8% | 110 | 30.2% | 34 | 27.0% | 8 | 34.8% | 2 | 40.0% |
One MMR dose | 85 | 14.6% | 97 | 26.6% | 39 | 31.0% | 4 | 17.4% | 0 | 0.0% |
Two MMR doses | 314 | 54.0% | 145 | 39.8% | 52 | 41.3% | 10 | 43.5% | 3 | 60.0% |
Unknown number | 15 | 2.6% | 4 | 1.1% | 1 | 0.8% | 0 | 0.0% | 0 | 0.0% |
Missing information | 17 | 2.9% | 8 | 2.2% | 0 | 0.0% | 1 | 4.3% | 0 | 0.0% |
Complications | ||||||||||
Orchitis | 20 | 3.4% | 19 | 5.2% | 7 | 5.6% | 0 | 0.0% | 0 | 0.0% |
Encephalitis | 3 | 0.5% | 3 | 0.8% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
Fever | 344 | 59.2% | 235 | 64.6% | 83 | 65.4% | 7 | 30.4% | 3 | 100.0% |
Time since second dose of MMR vaccine | ||||||||||
0–5 years | 89 | 28.3% | 45 | 31.1% | 9 | 17.3% | 4 | 40.0% | 1 | 33.3% |
≥ 6 years | 225 | 71.7% | 100 | 68.9% | 43 | 82.7% | 6 | 60.0% | 2 | 66.7% |
OUTBREAKS | Number of outbreaks | Outbreak related cases | Genotype G | Genotype D | Othersa | |||||
N | % | N | % | N | % | N | % | N | % | |
Total outbreaks | 51b | _ | 324 | _ | 20 | _ | 4 | _ | 3 | _ |
Year | ||||||||||
2007 | 31 | 60.8% | 166 | 51.2% | 16 | 80.0% | 0 | 0.0% | 1 | 33.3% |
2008 | 11 | 21.6% | 39 | 12.0% | 0 | 0.0% | 2 | 50.0% | 2 | 66.7% |
2009 | 2 | 3.9% | 9 | 2.8% | 2 | 10.0% | 0 | 0.0% | 0 | 0.0% |
2010 | 3 | 5.9% | 19 | 5.9% | 1 | 5.0% | 2 | 50.0% | 0 | 0.0% |
2011 | 4 | 7.8% | 91 | 28.1% | 1 | 5.0% | 0 | 0.0% | 0 | 0.0% |
Setting | ||||||||||
Family | 18 | 35.3% | 42 | 13.0% | 7 | 35.0% | 1 | 25.0% | 0 | 0.0% |
Secondary | 13 | 25.5% | 56 | 17.3% | 3 | 15.0% | 1 | 25.0% | 1 | 33.3% |
High school | 8 | 15.7% | 168 | 51.9% | 3 | 15.0% | 2 | 50.0% | 1 | 33.3% |
Occupational | 3 | 5.9% | 7 | 2.2% | 1 | 5.0% | 0 | 0.0% | 1 | 33.3% |
Community (discotheque, football team, neighbours) | 9 | 17.6% | 51 | 15.7% | 6 | 30.0% | 0 | 0.0% | 0 | 0.0% |